title: [Pharma-clinics. Drug of the month. Zaleplon (Sonata)].
abstract: Zaleplon (Sonata) is an original hypnotic derived from the pyrazolopyrimidine with a full agonistic activity on central benzodiazepine receptors B21 type. Zaleplon is characterized by an extremely short half-life (about 1 hour). At the 10 mg dose, it is an affective sleep inducer with limited risks of disturbances in morning performance. It is particularly suitable for the treatment of initial insomnia when the prescription of an hypnotic is justified.
authors.affiliation: Service de Psychiatrie et Psychologie médicale, Université de Liège.
authors.forename: M
authors.initials: M
authors.lastname: Ansseau
mesh_terms: D000081:Acetamides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*
chemical_list: D000081:Acetamides; D006993:Hypnotics and Sedatives; D011743:Pyrimidines; C085665:zaleplon